NRAS and metastatic melanoma: It has also been demonstrated that levels of mutant BRAF and NRAS ctDNA concentrations in patients with metastatic melanoma correlated with decreased metabolic activity monitored by fluorodeoxyglucose positron emission tomography (FDG-PET) in response to therapeutic interventions (Wong et al., 2017).